Skip to main content

Web Exclusives

Conference Highlights ASCO

PD-1 Inhibition with Dostarlimab Led to Remission in All Patients with Mismatch Repair-Deficient Rectal Cancer

Tafinlar plus Mekinist First Tumor-Agnostic Therapy Approved for Any Unresectable or Metastatic Solid Tumors with BRAF Mutation

Xalkori Now FDA Approved for the Treatment of ALK-Positive Inflammatory Myofibroblastic Tumor

Oncologists’ Common Misconceptions About Biosimilars Revealed in a Recent Survey

Peptide-Based CoVac-1 Vaccine Shows Promise Against COVID-19 in Patients with Cancer

Oncology Overview

NCCN Guidelines Update: Initial Colorectal Screening Lowered to Age 45

Yescarta First CAR T-Cell Therapy FDA Approved for Large B-Cell Lymphoma

Tibsovo Received a New Indication, in Combination with Azacitidine, for Newly Diagnosed Patients with AML and IDH1 Mutation

Kymriah Received Accelerated FDA Approval for Relapsed or Refractory Follicular Lymphoma

Vidaza Received New Indication for Patients with Newly Diagnosed Juvenile Myelomonocytic Leukemia

3
4
5
6
7
8
9

Page 6 of 36
Results 51 - 60 of 358